Dynavax Technologies Corporations, (Nasdaq: DVAX)biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Scott Myers to its Board of Directors and election as Board Chairman.

Scott has worked in the global pharmaceutical and medical technology industries for nearly three decades.  Most recently he was the Chief Executive Officer and served on the board of directors of AMAG Pharmaceuticals, Inc., where he led its turnaround and strategic sale to Covis Pharma in November 2020. Scott has served as Chairman of the board of directors of Rainier Therapeutics, Inc., an oncology biotechnology company focused on late-stage bladder cancer, from June 2018 to January 2020, and served as its Chief Executive Officer from September 2018 to January 2020. Prior to Rainier, Scott served as Chief Executive Officer, President and Director for Cascadian Therapeutics, Inc., an oncology company, from April 2016 through its acquisition by Seattle Genetics in March 2018. Scott is an independent director on the board of directors of Selecta Biosciences, Trillium Therapeutics, Inc. and Harpoon Therapeutics, Inc.

Scott holds a B.A. in Biology from Northwestern University and an M.B.A. from the Graduate School of Business (Booth) at the University of Chicago.

See Full Press Release Here